Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Agilent releases Infinity III LC series

December 2024—Agilent Technologies announced the release of its next-generation Agilent Infinity­Lab LC series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems as well as biocompatible versions of each system.

Trial shows MeMed BV reduces use of unnecessary antibiotics

December 2024—MeMed announced the completion of its first randomized controlled trial to evaluate the MeMed BV test in the United States. Results from this trial demonstrate the clinical utility of the MeMed BV test in promoting appropriate antibiotic use, highlighting its potential to improve patient outcomes and optimize health care decision-making. “This achievement is a critical step toward making MeMed BV the standard for distinguishing bacterial from viral infections and advancing efforts to expand reimbursement coverage,” according to a company press statement.

Qiagen expands QIAcuity dPCR assay portfolio

December 2024—Qiagen announced the launch of 100 assays for its digital PCR platform QIAcuity, for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and others. The assays are available through the company’s GeneGlobe platform, which integrates predesigned assays with a database of more than 10,000 biological entities, including genes, miRNAs, and pathways.

Bio-Rad expands EQAS program

December 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program. The liquid, independent, and confidential external assessment program consolidates 13 complex and highly tested specialty immunoassay analytes, including procalcitonin, active vitamin B12, interleukin-6, and fructosamine, at normal and abnormal levels.

FDA clears Accelerate Arc system

December 2024—Accelerate Diagnostics announced FDA 510(k) clearance of the Accelerate Arc system and BC kit for use with Bruker’s MALDI Biotyper CA system and MBT-CA Sepsityper software extension. The Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification using Bruker’s MBT-CA system.

NeoGenomics launches AML Express

December 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia. The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. The turnaround time is three to four days.

Pillar gets CPT code for FDA-approved OncoReveal CDx kit

December 2024—Pillar Biosciences has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit.

Siemens offers integrated automation on CI analyzer

December 2024—Siemens Healthineers now offers Atellica Integrated Automation on the Atellica CI analyzer, to consolidate 25 tasks, including sample management and decapping and sealing functionality, typically handled manually by clinical laboratory staff. With Atellica Integrated Automation, one technologist can manage calibration and QC, daily sorting, and archiving processes in minutes, according to a company press statement.

Biofidelity launches Aspyre Clinical Test for Lung

December 2024—Biofidelity announced the launch of its Aspyre Clinical Test for Lung for liquid biopsy samples. Using either a tissue or blood sample, the test detects somatic mutations from DNA and gene fusions from RNA within two days. “Currently, patients who are fortunate enough to receive molecular testing often have to wait weeks for the results, with many tests failing altogether,” Barnaby Balmforth, PhD, Biofidelity cofounder and CEO, said in a press statement. “Aspyre Clinical Test for Lung’s unmatched next-day turnaround time coupled with its best-in-class performance from tissue and blood and proven performance with challenging samples makes simplified genomic profiling via Aspyre a game-changer for patients and the clinicians treating them.”

Qiagen calls for increased TB testing in U.S. for at-risk people

December 2024—Qiagen has called for a sharper focus on testing strategies to stop new cases of tuberculosis from erupting and spreading in the United States. The U.S. has maintained one of the lowest TB rates in the world, but case counts across all age groups have risen every year since 2020, including a 16 percent increase in cases from 8,320 in 2022 to 9,615 in 2023 (Williams PM, et al. MMWR Morb Mortal Wkly Rep. 2024;73[12]:265–270). The American Academy of Pediatrics updated its TB screening guidelines this year to encourage use of blood-based testing for children of all ages, including from birth to two years old.